This annual seminar brought together top scientists and academics, senior politicians, policy analysts and other experts in order to debate this most difficult area of social policy.
The event incorporated four interlinked sessions:
1) The Beckley Foundation Global Drug Policy Seminar 2005, which evaluated the latest evidence and challenges in national and international drug policy and the effects of policy on supply, crime and health. The afternoon session examined the impact of international drug controlled systems on scientific and medical research.
2) The Beckley/Foresight Seminar on Future Policy Challenges, jointly hosted with Foresight, a UK Government think-tank, reviewed the Foresight Report on how best to manage the use of psychoactive substances for the good of the individual, the community and society over the next 20 years.
3) The Symposium of the International Network of Drug Policy Analysis, in which internationally acclaimed drug policy analysts met to give academic talks and discuss future collaboration.
4) The Meeting of the International Drug Policy Consortium, at which NGOs from around the world concerned with drug policy and related problems, met to discuss the future.
Law Enforcement and Supply Reduction, Dr Marcus Roberts, Head of Policy and Parliamentary Unit, MIND; Prof. Francisco Thoumi, Universidad del Rosario, Colombia
Reducing Drug-Related Crime: An overview of the global evidence, Dr Alex Stevens, University of Kent; Prof. Mark Kleiman, UCLA
Reducing Drug-Related Harm to Health, Prof. Gerry Stimson, Executive Director, International Harm Reduction Association; Dr Anindya Chatterjee, UNAIDS
The Medical Potential of Cannabis, Prof. Leslie Iversen, University of Oxford
The Effects of Medical Regulation of Cannabis in the USA, Robert Kampia, Executive Director, Marijuana Policy Project
The Scientific and Therapeutic Potential of Psychedelics, Prof. Dave Nicholls, Purdue University
Cognitive Enhancers: Blurring the Boundaries, Dr John Marsden, Institute of Psychiatry
Strategic Challenges, Dr Andrew Jackson, UK Government Office of Science and Technology
The Science Behind the Future of Recreational Drugs, Prof. David Nutt, University of Bristol
Harm Reduction and the Wider Social Context: Social, ethical and regulatory implications, Prof. Gerry Stimson, Executive Director, International Harm Reduction Association
Why Do People Use Drugs? Prof. Robert MacCoun, UC Berkeley
Is Evidence-Based Drugs Policy Possible? Prof. Mark Kleiman, UCLA
Blurring the Boundaries – The future of cognitive enhancers, Prof. Trevor Robbins, University of Cambridge; Prof. Barbara Sahakian, University of Cambridge
Ethical Dilemmas: Rights and responsibilities, Dr Harald Schmidt, Nuffield Council on Bioethics; Prof. Alastair Campbell, University of Bristol
Closing Discussion, Prof. Colin Blakemore, Executive Director, Medical Research Council; Dr Charles Schuster, Wayne State School of Medicine
To download the Proceedings Document: Global Drug Policy Seminar 2005, please click here.
The original paper on the scale of harms:
Nutt D, King LA, Saulsbury W & Blakemore C (2007). Development of a rational scale to assess the harm of drugs of potential misuse. The Lancet, 369(9566), 1047-1053.
An updated version of the paper:
Nutt DJ, King LA & Phillips LD (2010). Drug harms in the UK: a multicriteria decision analysis. The Lancet, 376(9752), 1558-1565.
One of the recurring themes of the Beckley Foundation seminars over the last few years has been highlighting the haphazard and inflexible nature of the current classification system for illegal drugs, which often bears little relationship to the real harms (and in some cases benefits) of the different substances, and omits any comparison with legal and prescribed drugs which can be even more dangerous to their users and more costly to society. Indeed, as the Government’s own Science and Technology Committee’s report, ‘Drug Classification: making a hash of it’ concludes:
“The classification system, purports to rank drugs on the basis of harm associated with their misuse, but we have found glaring anomalies in the classification system as it stands and a wide consensus that the current system is not fit for purpose …The problems we have identified highlight the fact that the promised review of the classification system is much needed and we urge the Government to proceed with the consultation without delay. We have proposed that the Government should develop a more scientifically based scale of harm, decoupled from penalties for possession and trafficking. In addition, we have argued that there is an urgent need for greater investment in research to underpin policy development in this area.”
This article has its roots in the talks given by Professor Colin Blakemore at two of the Beckley Foundation seminars: An Interdisciplinary Perspective on Alcohol and Other Recreational Drugs, held at Admiralty Arch, in collaboration with the Cabinet Office Strategy Unit, in 2003, and the Global Drug Policy Seminar at the House of Lords in 2004. This influential paper put forth a new scale of drug-related harms based upon the comparative classification of twenty substances. The paper, co-authored by Prof Blakemore and Prof David Nutt, et al. (2007), presents a scale of harms based on three scales – physical harm, dependence and social harm – which were independently assessed by two groups of experts from the fields of chemistry, pharmacology, forensic science, psychiatry and other medical specialties. The results, as shown below, are that the new scale of harm is quite inconsistent with the current ABC drug classification system in the UK. This new scale and the methods employed in its development offers a systematic framework and process that could be used by current regulatory bodies to assess the harm of current and future drugs of abuse, and can readily accommodate new evidence as and when it emerges.
Figure 1. Mean harm scores for 20 substances. Classification under the Misuse of Drugs Act, where appropriate, is shown by the colour of each bar. Nutt et al. (2007).
The Graph shows the overall mean scores of the independent expert group, averaged across all scorers, plotted in rank order for all 20 substances. The classification of each substance under the Misuse of Drugs Act is also shown. Although the two substances with the highest harm ratings (heroin and cocaine) are class A drugs, overall there was a surprisingly poor correlation between drugs’ class according to the Misuse of Drugs Act and harm score. Of both the eight substances that scored highest and the eight that scored lowest, three were class A and two were unclassified. Alcohol, ketamine, tobacco, and solvents (all unclassified at the time of assessment) were ranked as more harmful than LSD, ecstasy, and its variant 4-MTA (all class A drugs).
This system of classification, based on the scoring of harms by experts, on the basis of scientific evidence, has much to commend it and has long been recommended by the Beckley Foundation. This approach provides a comprehensive and transparent process for assessment of the danger of drugs, and builds on earlier approaches to this issue but covers more parameters of harm and more drugs. The system is rigorous and transparent, and involves a formal, quantitative assessment of several aspects of harm. It can easily be updated as knowledge advances. This system could therefore be usefully developed to aid in decision-making by regulatory bodies—e.g., the UK’s Advisory Council on the Misuse of Drugs and the European Medicines Evaluation Agency—to provide an evidence-based approach to drug classification.
Psilocybin for Depression
Type of publication